In mammals, an efficient multifaceted intestinal barrier system with physical, biochemical, and immunological components is crucial for the maintenance of tissue homeostasis to promote tolerogenic responses while protecting the host from infectious and toxic substances present in the environment. A defective epithelial barrier, often named ‘leaky gut’, has been demonstrated in autoimmune conditions such as type 1 diabetes (T1D), multiple sclerosis MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, the “Epithelial Barrier Hypothesis” has been proposed to contribute to the increase in multiple autoimmune disorders and chronic non-communicable diseases (NCD) worldwide. There have been many factors reported to dynamically regulate the gut mucosal barrier, such as dietary and chemical exposure, gut microbiota, microbial infections and intestinal immunity. However, to facilitate the development of therapeutic strategies to target and modulate intestinal barrier function, it is imperative to better define states of altered barrier function- ‘leaky gut’, advance our understanding of the mechanisms that promote leaky gut, and it’s association with diseases, along with potential causal mechanisms by which leaky gut promotes chronic inflammatory diseases.
This Research Topic aims to provide an overview of the current advances in the understanding of the impact of leaky gut on inflammation and autoimmune disorders, with a particular focus on the regulators of gut barrier function, the role of gut microbiota, the discovery of biomarkers for the identification of leaky barrier, the development of therapeutic approaches for prevention and/or early intervention of leaky barrier and autoimmune diseases.
In this Research Topic, we welcome submissions of Original Research, Review, Minireview, Report, Opinion and Methods articles that address, but are not limited to, the following subtopics:
1) The mechanism of leaky gut, microbial dysbiosis and bacterial translocation causing inflammation and autoimmunity
2) The role of gut microbiota in regulating mucosal barrier function, immune responses and autoimmune disorders
3) Factors and agents leading to defective gut barrier
4) Microbial infections, mucosal immunity and leaky gut
5) Methods and approaches to modify gut microbiota, mucosal barrier function and inflammation, such as diets, probiotics, prebiotics, bacteriophage and epithelial stem cells
6) The discovery of biomarkers for the identification of leaky barrier
In mammals, an efficient multifaceted intestinal barrier system with physical, biochemical, and immunological components is crucial for the maintenance of tissue homeostasis to promote tolerogenic responses while protecting the host from infectious and toxic substances present in the environment. A defective epithelial barrier, often named ‘leaky gut’, has been demonstrated in autoimmune conditions such as type 1 diabetes (T1D), multiple sclerosis MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, the “Epithelial Barrier Hypothesis” has been proposed to contribute to the increase in multiple autoimmune disorders and chronic non-communicable diseases (NCD) worldwide. There have been many factors reported to dynamically regulate the gut mucosal barrier, such as dietary and chemical exposure, gut microbiota, microbial infections and intestinal immunity. However, to facilitate the development of therapeutic strategies to target and modulate intestinal barrier function, it is imperative to better define states of altered barrier function- ‘leaky gut’, advance our understanding of the mechanisms that promote leaky gut, and it’s association with diseases, along with potential causal mechanisms by which leaky gut promotes chronic inflammatory diseases.
This Research Topic aims to provide an overview of the current advances in the understanding of the impact of leaky gut on inflammation and autoimmune disorders, with a particular focus on the regulators of gut barrier function, the role of gut microbiota, the discovery of biomarkers for the identification of leaky barrier, the development of therapeutic approaches for prevention and/or early intervention of leaky barrier and autoimmune diseases.
In this Research Topic, we welcome submissions of Original Research, Review, Minireview, Report, Opinion and Methods articles that address, but are not limited to, the following subtopics:
1) The mechanism of leaky gut, microbial dysbiosis and bacterial translocation causing inflammation and autoimmunity
2) The role of gut microbiota in regulating mucosal barrier function, immune responses and autoimmune disorders
3) Factors and agents leading to defective gut barrier
4) Microbial infections, mucosal immunity and leaky gut
5) Methods and approaches to modify gut microbiota, mucosal barrier function and inflammation, such as diets, probiotics, prebiotics, bacteriophage and epithelial stem cells
6) The discovery of biomarkers for the identification of leaky barrier
